Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock opened at $2.44 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.16 and a current ratio of 3.16. Aptevo Therapeutics has a one year low of $1.94 and a one year high of $7.55. The business has a 50 day simple moving average of $2.62 and a 200 day simple moving average of $3.21.

Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last posted its earnings results on Thursday, November 10th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.11. Research analysts anticipate that Aptevo Therapeutics will post -6.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Aptevo Therapeutics during the 2nd quarter worth approximately $46,000. Citadel Advisors LLC bought a new position in Aptevo Therapeutics in the 3rd quarter valued at $51,000. Bank of New York Mellon Corp bought a new position in Aptevo Therapeutics in the 1st quarter valued at $152,000. Renaissance Technologies LLC raised its position in Aptevo Therapeutics by 18.7% in the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Cantor Fitzgerald L. P. bought a new position in Aptevo Therapeutics in the 3rd quarter valued at $406,000. Institutional investors own 17.04% of the company’s stock.

Aptevo Therapeutics Company Profile

(Get Rating)

Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.